Giant warts in a kidney transplant patient: regression with sirolimus

1 Wolf P, Hofer A, Legat FJ et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009; 160:186–9. 2 Kircik L, Bagel J, Korman N et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008; 7:245–53. 3 Bashir MM, Sharma MR, Werth VP. TNF-a production in the skin. Arch Dermatol Res 2009; 301:87–91. 4 Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32:2130–5. 5 Sheppard J, Raza K, Buckley CD. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology 2007; 46:1623–4. 6 Patel RV, Clark LN, Lebowl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60:1001– 17. 7 Ji J, Shu X, Sundquist K et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 2009; 100:1499–502. 8 Stern RS, Leibman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998; 90:1278–84. 9 Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 year cohort study. J Invest Dermatol 2003; 120:211–16. 10 Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2):1–70.

[1]  N. Demartines,et al.  Human Papilloma Virus Type and Recurrence Rate After Surgical Clearance of Anal Condylomata Acuminata , 2009, Sexually transmitted diseases.

[2]  R. Margreiter,et al.  Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  F. Pruvot,et al.  Conversion to sirolimus: A useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  N. Park,et al.  Oncoprotein High Levels of Expression of the E7 Papillomavirus-containing Cells Leads to Differentiated Human Deregulation of Eif4e: 4e-bp1 In , 2005 .

[5]  N. Park,et al.  Deregulation of eIF 4 E : 4 EBP 1 in Differentiated Human Papillomavirus-Containing Cells Leads to High Levels of Expression of the E 7 Oncoprotein , 2006 .

[6]  G. Russ,et al.  Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. , 2006, Journal of the American Society of Nephrology : JASN.

[7]  G. Murphy,et al.  The impact of skin disease following renal transplantation on quality of life , 2005, The British journal of dermatology.

[8]  J. McGregor,et al.  Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. , 2005, The Journal of investigative dermatology.

[9]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[10]  M. Tremblay,et al.  The Immunosuppressant Rapamycin Represses Human Immunodeficiency Virus Type 1 Replication , 2002, Antimicrobial Agents and Chemotherapy.

[11]  J. Roujeau,et al.  Facteurs associés à l'apparition de verrues chez les transplantés d'organe. , 2002 .

[12]  J. Roujeau,et al.  [Risk factors for cutaneous wart onset in transplant recipients]. , 2002, Annales de dermatologie et de venereologie.